Browse Articles
Discover research articles across all indexed journals
Bronchoalveolar lavage single-cell transcriptomics reveals immune dysregulations driving COVID-19 severity
The continuous threats posed by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, including the emergence of potentially more infectious and deadly variants, necessitate ongoing studies to uncover novel and detailed mechanisms driving disease severity. Using single-cell transcriptomics, we conducted a secondary data analysis of bronchoalveolar lavage fluid (BALF) from COVID-19 patients of varying severities and healthy controls to comprehensively examine immune responses. We observed significant immune cell alterations correlating with disease severity. In severe cases, macrophages showed upregulation of pro-inflammatory genes TNFα and IL1β, contributing to severe inflammation and tissue damage. Neutrophils exhibited increased activation, marked by S100A8, CXCL8, and IL1β expression, with extended viability and reduced phagocytosis. Genes such as MCL1 and HIF1α supported extended viability, while MSR1 and MRC1 indicated reduced phagocytosis. Enhanced formation of neutrophil extracellular traps (NETs) and reduced clearance, indicated by NET-associated markers, were linked to thrombo-inflammation and organ damage. Both macrophages and neutrophils in severe cases showed impaired efferocytosis, indicated by decreased expression of MSR1 and TREM2 in macrophages and downregulation of FCGR3B in neutrophils, leading to the accumulation of apoptotic cells and exacerbating inflammation. Severe cases were characterized by M1 macrophages with high TNFα and IL1β, while milder cases had M2 macrophages with elevated PPARγ. Dendritic cells (DCs) in severe cases exhibited reduced proportions and attenuated expression of MHC class I genes (HLA-A, HLA-B, HLA-C) and co-stimulatory molecules (CD80, CD86), alongside increased cytochrome c expression, indicating impaired antigen presentation and enhanced apoptosis. NK and T cells in severe cases demonstrated altered receptor and gene expression, with increased activation markers IFNγ and ISG15, suggesting a paradoxical state of activation and exhaustion. This analysis highlights the critical role of dysregulated neutrophil, macrophage, dendritic cell, NK, and T cell responses in severe COVID-19, identifying potential therapeutic targets and providing novel insights into the disease.
Model sensitivity limits attribution of greenhouse gas emissions to polar bear demographic rates
Abstract Greenhouse gas emissions continue to increase and negatively affect sea ice conditions that polar bears rely on. It is therefore important to better understand how specific emissions levels affect polar bear demography. A recent study proposed a framework to address this issue, but sensitivity to decisions rules of the approach may limit its utility. We tested how sensitive the approach is to decisions rules related to sea ice concentration, choice of subpopulation boundaries, and modeling choices for bears in the Chukchi Sea and Southern Beaufort Sea subpopulations. We found that the number of ice-free days, number of fasting days, and when 10% of reproductive females exhibited recruitment failure varied considerably depending on equally-valid decisions rules versus those used in the existing study. Whereas the previous study suggested that both subpopulations surpassed the critical number of ice-free days that negatively affect recruitment, we found this threshold was never reached by the Southern Beaufort Sea subpopulation and only once for the Chukchi Sea subpopulation for the decision rules we considered. Our results suggest that the previously published approach is too sensitive to modeling assumptions and choice of decision rules to accurately evaluate the impacts of GHG emissions on polar bear demographic rates.
Association of myeloid-derived suppressor cell (MDSC) dynamics with clinical response to nivolumab in metastatic clear cell renal carcinoma patients (mRCC): Results from the I-RENE Meet-URO 8 study.
586 Background: Immune checkpoint blockade is a standard-of-care treatment for mRCC patients, but the immune mechanisms driving clinical benefit remain underexplored. In the I-RENE trial (NCT04891055), we conducted a comprehensive evaluation of myeloid-derived suppressor cell (MDSC) and lymphoid dynamics and their impact on the efficacy of nivolumab. Methods: The I-RENE study is a prospective, translational, real-world multicenter trial involving mRCC patients treated with nivolumab after failure of previous VEGFR-targeted therapies. Sixty patients were enrolled between December 2018 and August 2022. Peripheral blood (PB) samples were collected at baseline and at 2, 4, and 12 weeks, as well as at disease progression. PBMCs were analyzed by high-resolution flow cytometry (profiling 144 lymphoid and myeloid cell subsets), and plasma was assessed using multiplex analysis (69 soluble factors). CD14+ monocytes from PB and tumor tissue were subjected to RNA sequencing. Results: Significant immune modulations in PB were detectable as early as 2 weeks into treatment across all patients, regardless of clinical response, and persisted throughout the 3-month observation period. These changes included substantial alterations in the profiles of immune cells and plasma soluble factors. Responders to nivolumab exhibited a marked reduction in monocyte subsets associated with immune suppression, such as CD14+HLA-DR- cells, CD14+PD-L1+ cells, and intermediate monocytes. In contrast, non-responders showed a progressive increase in suppressive monocytes and a concomitant decrease in CD14+ cells involved in anti-tumor immunity, including non-classical monocytes and CD14+ cells expressing HLA-DR and CX3CR1. Lymphoid compartment analysis revealed that responders experienced an increase in CD8+ T cells and CD4+ effector memory T cells, along with a reduction in CD38+ T cells. Conversely, non-responders showed significant upregulation of senescent CD8+ T cells (KLRG1+CD28-CD57+) and CD38+ T cells. All progressing patients showed a notable resurgence of suppressive myeloid cells (HLA-DR-, PD-L1+), confirmed by an enriched MDSC gene signature, as well as an increase in PB CD38+ and senescent T cells. Notably, the detrimental role of myeloid-driven immune suppression in non-responders was further confirmed by an enriched MDSC gene signature in matched tumor samples. Conclusions: The pervasive and detrimental impact of myeloid cells committed to immune suppression is evident even before radiological progression in mRCC patients and persists despite immunotherapy. These findings highlight the need for early identification of immune-suppressive infiltrates and the development of strategies to overcome or reprogram these cells, both at the systemic and tumor level, following diagnosis.
Frequent overexpression of NECTIN-4 in CNS metastases from urothelial carcinoma.
804 Background: The combination of enfortumab vedotin plus pembrolizumab (EV/P) has become the new standard of care for advanced or metastatic urothelial carcinoma (mUC) due to its high efficacy. However, patients with active central nervous system (CNS) metastases were excluded from the EV-302 trial. More recently, NECTIN-4 amplifications have been identified as genomic predictors of EV response and long-term survival in patients with mUC. Additionally, early evidence suggests that EV may cross the blood-brain barrier and be effective in patients with CNS metastases. Therefore, we aimed to evaluate NECTIN-4 expression and amplification in patients with mUC involving CNS metastases. Methods: Immunohistochemical staining for NECTIN-4, with H-score evaluation, was performed in both non-CNS mUC (n=152) and CNS mUC patient cohorts (n=17). In addition, we developed a NECTIN-4-specific fluorescence in situ hybridization (FISH) assay to correlate NECTIN-4 copy number variations (CNVs) with membranous NECTIN-4 protein expression in CNS mUC. Results: Membranous NECTIN-4 protein expression was more abundant in CNS mUC (n=12/17; with H-score ≥ 100; median H-score 160; interquartile range [IQR] 250-85) than in non-CNS mUC samples (n=58/152; median H-score 40; IQR 0-140, p<0.001). Amplification data are currently being generated and will be presented at the conference. Conclusions: The substantial expression of NECTIN-4 in CNS metastases from UC, along with the results of the EV-302 trial and the identification of NECTIN-4 amplifications as genomic predictors of EV response and long-term survival in patients with mUC, supports the potential use of EV/P in treating patients with CNS mUC.
Clinical characteristics and treatment patterns of patients with muscle invasive bladder cancer: A real-world cohort study.
698 Background: Due to the evolving treatment landscape for muscle-invasive bladder cancer (MIBC), a better understanding of current treatment patterns among real-world patients is needed. This study reported demographic and clinical characteristics and examined the real-world treatment patterns of patients with MIBC in the US. Methods: This non-interventional, retrospective cohort study extracted data from the Inovalon Insights Payer-Sourced dataset, a claims database, from January 1, 2020–December 31, 2021. Patients aged ≥18 years with MIBC who were treated with cystectomy with or without neoadjuvant systemic treatment were followed from index date (first day of cystectomy or neoadjuvant systemic treatment) until the end of the study, loss of follow-up, diagnosis of metastasis, or end of enrollment in their medical or pharmacy health plan, whichever occurred first. Patients with metastasis from tumor types such as solid tumors, leukemia, lymphoma and, myeloma, with secondary malignancies, or participating in clinical trials by the index date were excluded. Results were reported for patients who received neoadjuvant and/or adjuvant treatment by therapy type. Results: Among 332 eligible patients, the mean (standard deviation [SD]) age was 64.3 (10.2) years, and 245 (73.8%) patients were male. Prior transurethral resection of a bladder tumor was reported for 236 (71.1%) patients. Common comorbidities were hypertension (198 [59.6%]), urinary tract infection (94 [28.3%]), diabetes without chronic complications (88 [26.5%]), and chronic pulmonary disease (80 [24.1%]). The mean (SD) age-adjusted Charlson Comorbidity Index was 6.3 (2.3). A total of 137 (41.3%) patients underwent cystectomy alone, while 195 (58.7%) patients received neoadjuvant systemic therapy followed by cystectomy. A total of 27 (8.1%) patients received both neoadjuvant and adjuvant therapies. In the 195 patients receiving neoadjuvant systemic therapies, 153 (78.5%) received chemotherapy with cisplatin; most commonly cisplatin + gemcitabine (76 [39.0%]) followed by cisplatin + doxorubicin + methotrexate + vinblastine (56 [28.7%]). Chemotherapy without cisplatin (41 [21.0%]) and immunotherapy (1 [0.5%]) were also given as neoadjuvant systemic therapies. Adjuvant therapies were received by 39 (11.7%) patients; of which, 20 (51.3%) received immunotherapy, 15 (38.5%) received chemotherapy with cisplatin, and 4 (10.3%) received chemotherapy without cisplatin. Cisplatin + gemcitabine (10 [25.6%]) and nivolumab monotherapy (10 [25.6%]) were the most common adjuvant treatments. Conclusions: Patients with MIBC had a substantial comorbidity burden. Many patients did not receive neoadjuvant or adjuvant treatment, indicating a persistent unmet need in this patient population for alternative therapeutic regimens. Further evaluation of treatment patterns is needed as the landscape evolves.
Neoadjuvant androgen deprivation therapy with enzalutamide plus the glucocorticoid receptor modulator relacorilant versus placebo for patients with high-risk localized prostate cancer.
TPS436 Background: Despite definitive local treatment, high risk localized prostate cancer (PC) patients (pts) have a 36-46% risk of biochemical recurrence (1). Neoadjuvant (NAJ) treatment with androgen receptor signaling inhibition (ARSI) improves pathologic outcome at the time of prostatectomy (2), and 3-year biochemical recurrence-free survival (bRFS) was strongly tied to pathologic complete response (pCR) plus minimal residual disease (MRD). One way to improve on this strategy is to target potential mechanisms of resistance to ARSI. A study of localized high-risk prostate cancer treated with NAJ ARSI plus androgen deprivation therapy (ADT) showed enrichment of glucocorticoid receptor (GR) expression in residual tumors (3). Inhibiting GR signaling decreases resistance to the ARSI enzalutamide (4). We previously demonstrated the safety of the combination of the selective GR modulator (SGRM) relacorilant plus enzalutamide (5). We have thus designed a study evaluating the efficacy of this combination given neoadjuvantly. Methods: This phase 2 study is a placebo-controlled randomized trial of 6 months of NAJ ADT and enzalutamide plus relacorilant/placebo (2:1). The primary objective of this study is response, measured by pCR and MRD at radical prostatectomy (RP). Eligible patients include those with localized histologically confirmed prostatic adenocarcinoma classified as high risk or very high-risk per NCCN guidelines. Enlarged lymph nodes below the iliac bifurcation are allowed. Following randomization pts will be treated with LHRH agonist plus enzalutamide with or without relacoriliant and undergo RP 1 month later. The total sample size is 90 patients with an interim analysis for futility conducted after 45 pts undergo RP. A chi-square test will be used to compare the proportion of patients achieving pCR/MRD. Assuming a true CR/MRD rate of 15% in the control group, 90 patients total would yield a power of 80% with a hypothesized CR/MRD of 32% in the relacorilant group, based on a one-sided test at the alpha=0.15 significance level. As secondary endpoints, we will evaluate radiographic response within the prostate with multiparametric MRI (mpMRI) imaging and the 3-year bRFS and MFS rates in both arms. Exploratory endpoints include demonstrating correlation between enhanced mpMRI imaging and pathologic response, as well showing decreased nuclear hormone receptor-driven proliferative gene expression in viable PC due to combined NAJ GR antagonism and ARSI compared to ARSI alone. The study is currently open and is seeking additional sites. 1. Falgario U, JAMA Netw Open 2023. 2. McKay R, J Urol 2021. 3. Efstathiou E, Eur Urol 2019. 4. Isikbay M, Horm Cancer 2014. 5. Desai, CCR , 2024. Clinical trial information: NCT05726292 .
Anti-irradiation reinforcement in NiFe/oxide composite structure by electronic reconstruction and structural stabilization for efficient magnetoresistive sensor in aerospace/radiotherapy applications
The construction of irradiation-tolerant anisotropic magnetoresistance (AMR) sensors is crucial for weak-field detection in scenarios of aerospace and radiotherapy. Presently, the utilization of the NiFe/oxide composite structure was considered to be an effective scheme to optimize the spin-dependent transport property; however, it exhibited poor anti-irradiation ability due to the crystal instability of oxide. Here, a strategy was proposed to break through the limitation based on the electronic reconstruction and structural stabilization. By introducing an oxygen-affinitive Hf intercalation into the Ta/MgO/NiFe/MgO/Ta multilayer, the electron coordination was modified to tune the 3d orbital occupancy of Fe, apparently boosting the s-d electron scattering and spin-related transport property. Meanwhile, the irradiation stability of electronic and crystal structures was effectively improved due to the emergence of the Hf–O–Mg bond with high dissociation energy. Therefore, we constructed a highly reliable AMR sensor with both the ultrahigh sensitivity of 3.1 mV/V/Oe and excellent irradiation-tolerant ability capable of resisting the γ-ray irradiation of 1000 Gy. These results not only build an important basis for the sensor application in the irradiation environment but also provide a possible idea for the anti-irradiation design in spintronic devices.
Pathology and parasitology of free-ranging coyotes from Tennessee and South Carolina
Coyotes are exposed to many parasites and pathogens of veterinary and zoonotic concern. To assess the prevalence of the diseases caused by these microbes, we opportunistically obtained coyote samples from a variety of sources including a GPS collaring study, rabies testing facilities, wildlife resources agents, and road-side mortalities. We performed necropsies, serological testing, fecal flotations, and molecular analyses on coyotes from Tennessee and South Carolina. Dirofilaria immitis (heartworm) infected 46% (41/89) of coyotes and was associated with eosinophilic alveolitis and arteritis. Paragonimus kellicotti, a zoonotic lung fluke, was found in 24% (17/71) of Tennessee coyotes, including one coyote with extrapulmonary infection affecting the liver and lymph nodes. Trichinella spp., a zoonotic nematode, was present in 17% (12/71) of Tennessee coyotes but was not associated with muscular inflammation. Sarcoptes scabiei, the causative agent of sarcoptic mange, was detected in one Tennessee coyote. Most coyotes (86% [90/105]) were seropositive for Toxoplasma gondii, while 8.5% (9/106) were seropositive for Trypanosoma cruzi, an emerging zoonotic, vector-borne parasite. This study demonstrated that coyotes are commonly exposed to numerous parasites and pathogens that affect people and pets and are excellent sentinels for these diseases.
Vericiguat prevents high glucose-mediated impaired vascular smooth muscle cGMP production and vasorelaxation
Risk stratification using the Decipher 22-gene genomic classifier (GC) and digital pathology artificial intelligence (DPAI) in nearly 10,000 localized prostate cancer patients.
408 Background: DPAI models have recently demonstrated the potential to improve risk stratification beyond routine clinical and pathologic variables. However, it is not known whether integrating DPAI information will enhance the prognostic accuracy of validated gene expression tests. In this study, the prognostic performance of novel DPAI algorithms were assessed in context to the genomic classifier (GC). Methods: A prospectively collected cohort of 9,874 patients with localized prostate cancer was retrieved from the Veracyte GRID registry (NCT02609269). Scans at 40X magnification were obtained for 17,701 H&E slides using an Aperio GT450 scanner (Leica). An open-source whole-slide pathology foundation model (GigaPath) was used to encode whole slide image (WSI) patches into digital pathology image features (DPIF). Attention-based multiple instance learning approach was used to develop separate models to predict distant metastasis (DM) in the biopsy and radical prostatectomy (RP) training subsets. WSI, baseline clinical variables, and GC scores were linked using tokenization (Datavant) to real-world data (Clarivate). The primary endpoint of this study was DM. Adjusted Hazard ratio (aHR) from multivariable Cox regression (MVA) modeling and 5-year area-under curve (AUC) estimates were used to compare models using DPIF. Results: Median follow-up for the training cohort (n=6,705; 239 DM events) and validation (n=3,169; 110 DM events) cohorts were 6.5 years. In the biopsy validation cohort of 999 patients, the GC predicted DM with an AUC of 0.80 (95% CI, 0.70-0.90), which exceeded NCCN risk group alone (AUC 0.68, 0.56-0.80) and DPAI (AUC 0.76, 0.66-0.86). MVA including age, NCCN, GC score, and DPAI, only showed GC (aHR 1.23 [1.03, 1.47]) and DPAI (aHR 1.22 [1.04, 1.43]) to be significantly associated with risk of DM (aHR per 10%, both p<0.05). However, an integrated model with clinicopathologic features, DPAI, and GC did not improve discrimination (AUC 0.80, 0.70-0.90). In the RP validation cohort of 1,492 patients, GC predicted DM with an AUC of 0.81 (95% CI, 0.73-0.88). An integrated model with clinicopathologic features, DPAI, and GC improved the AUC to 0.84 (0.77- 0.91). In MVA, only RP GC (aHR 1.27 [1.13, 1.43]) and DPAI (aHR 1.44 [1.23, 1.69]) were significant predictors for DM (both p<0.001). Conclusions: To our knowledge, this is the largest study assessing the prognostic value of adding DPAI to improve performance above and beyond a clinical-genomic model. The results from this study suggest that the combination of these data sources may further improve prognostication, and use of both DPAI and genomics negated information from routine clinical variables. Ongoing efforts in larger cohorts are underway to identify optimal scenarios in which GC and DPAI information enhance clinical utility for decision making.
Trends in kidney cancer: Exploring the impact of sex and age on stage of disease, and prognosis during the past three decades in Denmark—A DaRenCa study.
485 Background: Over the past 30 years, renal cell carcinoma (RCC) management has undergone significant advancements, driven by increased diagnosis through imaging scans and the development of more effective systemic therapies for metastatic disease. Understanding the impact of early detection and evolving treatment strategies on patient outcomes is crucial for guiding future advancements in RCC care. This nationwide registry-based cohort study investigates how the number of RCC cases, stage at diagnosis, and prognosis have changed during the past 30 years in Denmark, and how these are associated with sex and age. Methods: A population-based cohort was established, including all Danish patients aged 18 and older diagnosed with RCC from 1992 to 2021, excluding individuals with a prior cancer history. Patients were identified and followed from the date of diagnosis until death or end of follow-up using nationwide register data. Comorbidities prior to RCC diagnosis were assessed using nationwide hospital admittance records. Results: A total of 17,423 RCC patients were diagnosed during the past 30 years in Denmark. The male-to-female ratio changed significantly from 0.59:0.41 in 1992-1996 to 0.72:0.28 in 2017-2021 (P < 0.001). The age distribution of patients at diagnosis remained relatively constant (ranging from 65-67 years). The number of RCC cases increased from 2,244 in 1992-1996 to 3,947 in 2017-2021. We observed stage migration over time, with Stage I cases increasing from 30% in 2002-2006 to 55% in 2017-2021, and Stage IV cases decreasing from 45% in 2002-2006 to 20% in 2017-2021, while the absolute number of metastatic cases remained relatively unchanged. The median survival of patients with metastatic disease steadily increased by 314% from 4.1 months in 1992-1996 to 12.9 months in 2017-2021. Additionally, married patients showed better survival than divorced and unmarried patients. Conclusions: During the past 30 years, the number of RCC cases in Denmark has increased, primarily driven by early-stage tumors, while the number of metastatic cases has remained stable. Additionally, the proportion of female patients has decreased across all stages of RCC during the observation period. Overall survival has significantly improved over time, highlighting the impact of early detection and treatment advancements. Despite only studying Danish patients, this study serves as a reference for how patient dynamics have evolved with the advancements in the diagnosis and treatment of RCC.
Targeting TROP2 in aggressive variant and neuroendocrine prostate cancer.
171 Background: Aggressive variant prostate cancer (AVPC) including neuroendocrine prostate cancer (NEPC) is characterized by rapid, androgen-independent tumor growth. Standard therapies often show limited efficacy. Alternative treatment strategies are therefore urgently required. Here, we present preclinical and first clinical results on the potential impact of TROP2 targeting in AVPC/NEPC. Methods: TROP2 expression was assessed in AVPC/NEPC cell lines, circulating tumor cells (CTCs) and metastatic biopsies. Efficacy of the TROP2 targeted antibody drug conjugate (ADC) Sacituzumab Govitecan (SG) was evaluated in prostate cancer (PC) cell lines with high and low/- TROP2 expression. TROP2+ AVPC/NEPC patients with exhausted standard therapy options are currently undergoing treatment with SG in an individual approach. Results: TROP2 expression was detected at varying levels in PC cell lines, with increased expression in docetaxel-resistant cells. CTCs of AVPC and NEPC patients were TROP2+ in 74.0% (37/50) and 48.6% (17/35), respectively, while the vast majority of biopsies from both cohorts expressed TROP2. SG was highly effective in TROP2+ cells in vitro , regardless of their degree of resistance to standard therapies while reduced activity was seen in TROP2 low/- cells after short-term exposure. Remarkably, SG exhibited a pronounced antiproliferative effect and/or apoptosis induction in TROP2-low LNCaP and PC3 cells, when co-cultured with TROP2+ DU145-DR or PC3-DR cells, indicating a bystander effect. The antiproliferative activity of SG was attributed to an increased G2/M cell cycle arrest. Proteomic analyses suggested suppression of cell cycle related processes and proliferation as well as signaling pathways involved in neuronal dedifferentiation and cell stemness. First clinical results of heavily pretreated TROP2+ AVPC/NEPC patients (n=9) revealed partial remission (PR) or stable disease in 44% and 33% at radiological follow-up, with a disease control rate of 78% and 44% at 3 and 6 months, respectively. Of note, in a NEPC patient with sudden, rapid progression following initial PR, loss of TROP2 expression on CTCs was detected. In addition, preclinical data suggested AKT activation and upregulation of p-glycoprotein as further possible resistance mechanisms. Conclusions: TROP2-directed therapy with SG demonstrates promising preclinical and clinical activity in AVPC and NEPC. A clinical trial evaluating a TROP2-directed ADC in AVPC is in preparation.
Observational study of tislelizumab (Tisle) combined with pazopanib in reducing venous tumor thrombus in clear cell renal cell carcinoma with venous invasion.
481 Background: Renal cell carcinoma with venous tumor thrombus (RCC-VTT) presents significant surgical challenges, often requiring complex interventions. Neoadjuvant therapies that can reduce primary tumor size and venous tumor thrombus may simplify surgical procedures and decrease associated risks. Methods: The data of pts with RCC-VTT who underwent Tisle combined with Pazopanib neoadjuvant therapy at the First Affiliated Hospital of Xinjiang Medical University from Nov. 2021 to Jan. 2024 were analyzed. Inclusion criteria were as follows: (1) age ≥ 18 years; (2) TNM stage T3-4N0-1M0-1; (3) Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1; (4) a life expectancy of at least 3 months; and (5) adequate bone marrow, kidney, liver function, and normal blood test results. Exclusion criteria were as follows: (1) prior treatment with other antitumor drugs; (2) recent history of cardiac or vascular events or other conditions precluding surgical treatment; (3) participation in other clinical trials within the past 3 months; (4) lack of legal capacity or limited legal capacity; and (5) contraindications, allergies, or adverse reactions to pazopanib and tislelizumab. Eligible Pts received Tisle 200 mg IV. in day 1(D1), every 21 days for 4 cycles; Pazopanib was administered orally at a dose of 800 mg once daily for 12 weeks prior to the scheduled surgery. The primary endpoint of the study was the percentage change in the length of the VTT and the percentage reduction in the longest tumor diameter. Results: Nine patients with a median age of 58 years were treated. The median reduction in tumor diameter was 31.0% (range: 3.0%–48.7%), and the median reduction in VTT length was 29.2% (range: -153.1% to 100.0%). Treatment led to decreased surgical complexity in 88.9% of patients. The regimen was well-tolerated, with manageable adverse events primarily including vomiting, itching, and weight loss. No metastasis developed during the study period, though one patient required expedited surgery due to an increase in thrombus size. Conclusions: The combination of tislelizumab and pazopanib as neoadjuvant therapy effectively reduces the size of tumors and associated venous tumor thrombi in patients with RCC-VTT, facilitating less complex surgical interventions and potentially leading to better postoperative outcomes.
Giant persistent photoconductivity at room temperature in Sn-based perovskites
Long avoided due to adverse effects in traditional optoelectronic devices, persistent photoconductivity (PPC) is now sought-after for emerging technologies, including artificial synapses and coupled solar batteries. We report on a giant PPC effect at room temperature in the mixed Sn/Pb-based perovskite MAPb0.5Sn0.5I3 (MA = methylammonium). Using Hall and photo-Hall measurements, we identify macroscopic separation of negative and positive carriers as the most likely origin for delayed photoconductivity decay, with a strong electron localization expected at grain boundaries or cracks within the polycrystalline films. Additionally, measurements on perovskite films with varying morphology and SnF2 additive content reveal that large apparent grain size (&gt;5 μm) and effective passivation of recombination centers combine to provide a path for achieving PPC extending over 100 h at room temperature.
Effect of organizational change on employee innovation performance: A dual mediation model
Affected by the COVID-19 pandemic and the international development pattern, the international environment has undergone profound changes. Enterprises, as the main body of activities on the front line of production and operation and the main battlefield of market competition, are facing various risk challenges. In both domestic and international markets, these challenges are becoming increasingly complex for businesses to navigate. For theoretical research, the impact of organizational change on employee innovation performance has become a key issue in organizational behavior and human resource management research. However, the influence mechanism of organizational change on employee innovation performance is still unclear. In this study, we examine whether, how, and when organizational change increases employee innovation performance in accordance with job demands-resource theory, as well as the effect of work pressure and work engagement on employee innovation performance. Data from 289 employees at three time points are examined. The results show that: (1) Organizational change negatively affects employee innovation performance through work pressure, i.e., work pressure mediates the impact of organizational change on employee innovation performance. (2) Organizational change positively affects employee innovation performance through work engagement, i.e., work engagement mediates the impact of organizational change on employee innovation performance. (3) Organizational identity plays a moderating role between organizational change and work pressure and work engagement, respectively, and there is a moderating effect in the process of mediation of work pressure and work engagement. The findings of this study provide important insights into how and when organizational change influences employee innovation performance.
A novel in silico molecular tool for comprehensive differentiation of Mycobacterium species
Abstract The Identification of various mycobacterial species is critical for understanding their pathogenicity and epidemiology. Despite the existence of several established methods for identifying mycobacterial species, each of these methods has several significant limitations, including high costs, substantial time demands, and a restricted ability to detect a wide range of recoverable species. This study presents an in silico method using restriction fragment length polymorphism (RFLP) to differentially identify 75 clinically important mycobacterial species.The present investigation employed specific primer combinations to identify and generate a distinct hypervariable sequence across the ribosomal RNA gene. This unique sequence using appropriate restriction enzyme digestion followed by gel electrophoresis enabled the creation of highly precise and distinct patterns or profiles for each of the 75 medically relevant Mycobacterium species, including members of closely related Mycobacterium complex groups. This approach can quickly and reliably identify mycobacterial species, allowing for more timely treatment decisions and contributing to beneficial epidemiological investigations.
Avelumab first-line (1L) maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic: Updated real-world results from a national reimbursement registry.
693 Background: Platinum-based chemotherapy followed by avelumab 1L maintenance treatment for patients with nonprogressive disease is a standard of care in la/mUC. In the Czech Republic, following EU approval, there is a requirement to provide real-world data for “highly innovative medicinal products” and obtaining reimbursement requires registry creation for data collection. Interim results from a retrospective analysis of a national reimbursement registry for avelumab 1L maintenance treatment in the Czech Republic were reported previously; here, we report longer-term results. Methods: Registry data were collected by the Health Insurance Bureau for patients with la/mUC receiving avelumab 1L maintenance treatment between Oct 2021 and Jan 2024. The primary endpoint was overall survival (OS) from start of avelumab 1L maintenance (index date); secondary endpoints included progression-free survival (PFS) and safety. Descriptive statistics were used to analyze the data. OS, PFS, and probability of ongoing response were estimated using the Kaplan-Meier method. Results: Overall, 107 patients with la/mUC were treated with avelumab 1L maintenance (77 male/30 female). 1L platinum-based chemotherapy was cisplatin based in 55 patients (51.4%) and carboplatin based in 46 patients (43.0%); 6 patients (5.6%) switched regimens. At the start of avelumab, median age was 72 years (range, 45-92), and 41 patients (38.3%) had visceral metastases. Median follow-up was 8.2 months (range, 0-26.2). Median duration of avelumab treatment was 9.7 months (range, 1.0-29.2). The table shows effectiveness data for avelumab 1L maintenance. Overall, 16 adverse events were reported in 18 patients (16.8%), including 1 patient with a grade 3 infusion reaction and 2 patients with grade 2 diarrhea. At data cutoff (Jan 31, 2024), 88 patients were alive, and 23 had started subsequent treatment. Conclusions: These updated data are generally consistent with results from the JAVELIN Bladder 100 phase 3 trial and other real-world studies, supporting the effectiveness and favorable safety profile of avelumab as 1L maintenance treatment in patients with la/mUC that has not progressed with 1L platinum-based chemotherapy. N=107 Median OS, months Not reached OS rate, % (95% CI) 6 months12 months18 months 93.4 (88.4-98.7)79.3 (69.8-90.2)68.0 (54.6-84.6) Median PFS, months (95% CI) 11.0 (8.6-not estimable) PFS rate, % (95% CI) 6 months12 months18 months 67.8 (58.7-78.2)48.9 (38.8-61.6)39.1 (27.5-55.4) Objective response rate, n (%) Complete response Partial response 29 (27.1)12 (11.2)17 (15.9) Median duration of response, months Not reached Probability of ongoing response, % (95% CI) 6 months12 months18 months 91.1 (80.0-100)80.4 (64.7-99.8)80.4 (64.7-99.8) Median time to response, months 3.4 (1.8-18.2)
Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies.
501 Background: Since its approval, PD-1/PD-L1 IO therapies are used greatly among patients with mRCC. However, outcomes in the post-IO setting are not well characterized. This study aims to characterize the treatment patterns and clinical outcomes of patients with mRCC who have experienced progression following IO therapy. Methods: A retrospective review of electronic health records from a US community oncology network included patients with mRCC who progressed on their initial IO therapy and received subsequent therapies between 01/01/2018 and 01/31/2023. The index regimen was defined as the therapy administered after the initial IO therapy, and the index date marked the initiation of this index regimen. The index line of therapy (LOT) was defined as the treatment setting in which index regimen was used. Descriptive statistics were used to summarize patient characteristics and treatment patterns. Real-world progression free survival (rwPFS) and overall survival (OS) were analyzed by Kaplan–Meier method. Log-rank tests were performed to compare outcomes across various Index LOTs and index regimen classes. Results: The study identified 299 patients with a median age of 68 years (IQR 60-75). Among them, 72.7% were male, 84.7% were white, and 87.4% had an intermediate/poor risk score according to the international metastatic RCC database consortium. The index regimen was given as follows: 1.7% in first line (1L), 67.9% in 2L, and 30.4% in 3L. Tyrosine kinase inhibitor (TKI) monotherapy was the most common index regimen class (62.2%) with cabozantinib being the most used regimen (46.5%). Over a median follow up of 11.3 months, median (95% CI) rwPFS and OS were 6.0 (5.4, 6.8) and 14.3 (12.1, 16.4) months, respectively. No differences were observed in rwPFS and OS across index LOTs (rwPFS p= 0.763; OS p= 0.885) or index regimen classes (rwPFS p= 0.721; OS p= 0.747, Table 1.). Conclusions: Treatment outcomes in the post-IO setting for mRCC patients are limited. TKI monotherapies are the most common treatments in this setting. No difference was found in OS or rwPFS across index LOTs and index regimen classes. Novel treatments are needed to improve clinical outcomes in these setting. Subgroups N Median rwPFS (95% CI) Median OS (95% CI) Overall 299 6.0 (5.4, 6.8) 14.3 (12.1, 16.4) Index Regimen 2L* 203 6.0 (5.0, 7.1) 14.1 (11.5, 16.3) Index Regimen 3L 91 6.0 (5.1, 8.2) 14.5 (11.6, 20.1) Index Regimen Class: IO + IO** 25 3.6 (2.8, 6.7) 19.7 (12.4, 33.3) Index Regimen Class: IO + TKI 52 5.4 (3.6, 8.0) 13.4 (9.6, 23.8) Index Regimen Class: TKI Only 186 6.7 (5.6, 8.5) 14.4 (11.6, 16.7) Index Regimen Class: Other 28 5.4 (2.9, 8.0) 13.9 (6.9, 26.9) *Due to small sample sizes of the index regimen 1L, log-rank test was performed between index regimen 2L and 3L subgroups. **Due to small sample sizes of IO only subgroup, log-rank test was performed among IO + IO, IO + TKI, TKI only, and other subgroups.
Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.
437 Background: CheckMate 214 established nivolumab and ipilimumab (NIVO+IPI) as a first line standard of care regimen with superior survival and durable response versus sunitinib (SUN) in advanced RCC. Previous studies have shown that high levels of circulating KIM-1 are associated with worse prognosis and reduction in KIM-1 levels is associated with benefit from adjuvant immunotherapy. In this post-hoc analysis we evaluated whether KIM-1 levels at baseline and after 1 cycle of NIVO+IPI or SUN are associated with treatment outcomes in CheckMate 214. Methods: Patients with advanced RCC were randomized to NIVO+IPI or SUN as previously described. Serum KIM-1 was measured at baseline and 3 wks after first treatment dose using an enzyme based electrochemiluminescence assay. The association between KIM-1 levels and clinical outcomes was evaluated using Kaplan-Meier and Cox proportional hazards analyses. Results: We analyzed serum from 821 patients (75% of the CM 214 ITT population). Median KIM-1 at baseline was 660.4 pg/mL. Across both arms, higher KIM-1 levels were associated with shorter overall survival (OS) independent of IMDC risk group, nephrectomy status, and tumor burden. Benefit for NIVO+IPI versus SUN was seen across KIM-1 tertiles. Decrease in KIM-1 from baseline to C2D1 was strongly associated with progression free survival (PFS) and OS among patients treated with NIVO+IPI (Median PFS 70.8 months vs 4.2 months for patients with >30% decrease vs >30% increase in KIM-1, with median OS 85.4 vs 26.6 months, overall response rate (ORR) 69.3 % vs 13.9%), but not in patients treated with SUN. Conclusions: In CheckMate 214, increased levels of baseline circulating KIM-1 were associated with worse clinical outcomes both in NIVO+IPI and SUN arms. The extent of reduction in serum KIM-1 just 3 wks after single cycle of NIVO+IPI was associated with long term efficacy of this IO doublet. Circulating KIM-1 may be a useful minimally invasive biomarker for monitoring patients on RCC immunotherapy. KIM-1 change at 3 weeks (prior to second dose of NIVO+IPI) and association with outcomes (NIVO+IPI arm). 3 week KIM-1 change N (%) ORR, % (95% CI) mPFS, months (95% CI) mOS, months (95% CI) >30% Decrease 140 (31.7) 69.29 (60.94-76.80) 70.80 (17.84- NA) 85.36 (63.08- NA) >10-30% Decrease 87 (19.7) 36.78 (26.69-47.80) 11.43 (6.28-18.20) 66.14 (40.44-80.10) <10% Change 86 (19.5) 30.23 (20.79-41.08) 15.41 (10.32-20.73) 52.70 (30.26-70.67) >10-30% Increase 56 (12.7) 23.21 (12.98-36.42) 7.13 (4.17-16.79) 40.34 (23.82-58.41) >30% Increase 72 (16.3) 13.89 (6.87-24.06) 4.17 (3.02-8.08) 26.61 (18.79-38.44)
A heterologous prime-boost strategy using RUTI vaccine to improve the BCG response in non–muscle-invasive bladder cancer patients (RUTIVAC-1 trial).
801 Background: Despite standard-of-care therapy with transurethral resection of bladder tumor and intravesical BCG instillation, a significant percentage of patients with non-muscle invasive bladder cancer (NMIBC) experience disease recurrence or progression. Therefore, novel combination therapies are needed to improve BCG efficacy. The RUTIVAC-1 trial, a randomized, double-blind, placebo-controlled, phase I study, was conducted to investigate the potential of a heterologous prime-boost strategy using RUTI, a nonlive vaccine composed of Mycobacterium tuberculosis cell wall fragments, as a primer to enhance the intravesical BCG-induced immune response in NMIBC patients. Methods: Forty high-grade, BCG-naïve NMIBC patients were randomized 1:1 to receive two subcutaneous doses of either placebo or RUTI (25 μg) before standard BCG treatment. The primary endpoint was the immunological changes after RUTI vaccination. Secondary endpoints included clinical efficacy (recurrence, progression and mortality rates) and safety at 5-year follow-up. Results: Baseline characteristics were similar in both groups (median age 70 years, 90% male, 65% T1, 32.5% Ta and 4% CIS). RUTI vaccination induced a vaccine-specific CD4 + and CD8 + T cell response prior to the initiation of intravesical BCG therapy. Following intravesical BCG treatment, the placebo group showed an increase in regulatory T cells (Tregs; CD4 + CD25 + CD27 + ), which was not observed in the RUTI group. Conversely, RUTI-vaccinated patients exhibited a more heterogeneous and polyfunctional specific immune response, with significant increases in PPD-specific CD25 + , CD137 + , OX40 + and CD69 + CD4 + T cells, as well as bi- and trifunctional CD4 + T cells expressing IFN-γ, TNF-α, and IL-2. Efficacy after 5 years of follow-up correlated with immunological changes, with RUTI vaccination associated with a significant increase in progression-free survival (100% vs. 72.2%; p=0.015), an 80% reduction in the risk of experiencing an event (EFS 89.5% vs. 50%; HR: 0.2, 95% CI 0.06–0.69; p=0.024) and a higher cancer-specific disease-free survival rate (100% vs. 83.3%; p=0.067). RUTI was safe, with only low-grade injection site reactions and no systemic effects. Conclusions: RUTI vaccination prior to intravesical BCG treatment in NMIBC patients is safe and effectively modulates the BCG-induced immune response, promoting a more balanced effective/suppressive response. This novel approach has the potential to significantly improve clinical outcomes in the management of NMIBC. Clinical trial information: NCT03191578 .